70631-88-8

Upstream product

• 69797-47-3 4-(3-fluoro-phenyl)-4-oxo-butyric acid methyl ester 
• 1231765-06-2 ethyl 4-(3-fluorophenyl)butanoate 
• 625-38-7 but-3-enoic acid 
• 768-35-4 3-fluorophenylboronic acid 
• 455-36-7 1-(3-fluorophenyl)ethanone 
• 456-48-4 3-Fluorobenzaldehyde 
• 51114-94-4 (2-carboxyethyl)triphenylphosphonium bromide 
• 462-06-6 fluorobenzene 
• 69797-46-2 4-(3'-fluorophenyl)-4-oxo-butanoic acid 
• 1254715-20-2 C₁₅H₁₉FO₄ 
• 134464-81-6 C₁₁H₁₃FO₂ 
• 127404-67-5 4-(3-fluoro-phenyl)-but-3-enoic acid 

Downstream Products

• 703-67-3 6-fluoro-3,4-dihydronaphthalen-1(2H)-one 
• 13790-88-0 7-fluoro-1-tetralone oxime 
• 2840-44-0 7-fluoro-3,4-dihydronaphthalen-1(2H)-one 
• 93742-85-9 5-fluoro-3,4-dihydronaphthalen-1(2H)-one 
• 895534-20-0 (R)-6-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-1-ol 
• 880544-30-9 C-(6-benzenesulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-methylamine 
• 880544-27-4 (6-benzenesulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-(4,5-dihydro-1H-imidazol-2-yl)-amine 
• 149915-80-0 6-phenylsulfanyl-3,4-dihydro-2H-naphthalen-1-one 
• 895132-99-7 6-Benzenesulfonyl-3,4-dihydro-2H-naphthalen-1-one 
• 895534-13-1 6-benzenesulfonyl-3,4-dihydro-naphthalene-1-carbonitrile 
• 895534-14-2 6-benzenesulfonyl-1,2,3,4-tetrahydro-naphthalene-1-carbonitrile 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed to adenine analogs, methods of making adenine analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis,

Ligand-Controlled Regiodivergence in Nickel-Catalyzed Hydroarylation and Hydroalkenylation of Alkenyl Carboxylic Acids**

A nickel-catalyzed regiodivergent hydroarylation and hydroalkenylation of unactivated alkenyl carboxylic acids is reported, whereby the ligand environment around the metal center dictates the regiochemical outcome. Markovnikov hydrofunctionalization products are obtained under mild ligand-free conditions, with up to 99 % yield and >20:1 selectivity. Alternatively, anti-Markovnikov products can be accessed with a novel 4,4-disubstituted Pyrox ligand in excellent yield and >20:1 selectivity. Both electronic and steric effects on the ligand contribute to the high yield and selectivity. Mechanistic studies suggest a change in the turnover-limiting and selectivity-determining step induced by the optimal ligand. DFT calculations reveal that in the anti-Markovnikov pathway, repulsion between the ligand and the alkyl group is minimized (by virtue of it being 1° versus 2°) in the rate- and regioselectivity-determining transmetalation transition state.

Synthesis of Novel Pterocarpen Analogues via [3?+?2] Coupling-Elimination Cascade of α,α-Dicyanoolefins with Quinone Monoimines

By employing triethylamine as a catalyst, [3?+?2] coupling-elimination cascade of α,α-dicyanoolefins with quinone monoimines was realized. The reactions afforded various novel pterocarpen analogues with generally moderate yields (up to 75%). In addition, a plausible reaction mechanism was proposed.

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES

Methods for producing a compound of formula k1 or k2 by reducing a dihydronapthalene amide compound of formula i with hydrogen gas in the presence of a ruthenium catalyst of formula j1 or j2 [in-line-formulae]Ru(Z)2(L)??j1;[/in-line-formulae] [

Arylsulfonyl naphthalene derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, q, Ar, R1, R2 and R7 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Compounds of the formula I, II or III; or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS

Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R 2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula (I).

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R2 is (CR3R4)n-NR5R6 and m, p, q, Ar, R1, R3, R4, R5 and R6 are as defined in the claims, which are selective antagonists of 5-HT6 and/or 5-HT2A. Also provided are compositions comprising these compounds and their use in the preparation of medicaments for treating central nervous system disease states selected from psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson’s disease, amyotrophic lateral scierosis, Alzheimer’s disease, food uptake disorders and Huntington’s disease.